Terms: = Brain cancer AND TOP2A, TOP2, TP2A AND Prognosis
11 results:
1. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Shirai Y; Ueno T; Kojima S; Ikeuchi H; Kitada R; Koyama T; Takahashi F; Takahashi K; Ichimura K; Yoshida A; Sugino H; Mano H; Narita Y; Takahashi M; Kohsaka S
J Neurooncol; 2024 Mar; 167(1):75-88. PubMed ID: 38363490
[TBL] [Abstract] [Full Text] [Related]
2. Targeted sequencing of cancer-related genes reveals a recurrent top2a variant which affects DNA binding and coincides with global transcriptional changes in glioblastoma.
Gielniewski B; Poleszak K; Roura AJ; Szadkowska P; Jacek K; Krol SK; Guzik R; Wiechecka P; Maleszewska M; Kaza B; Marchel A; Czernicki T; Koziarski A; Zielinski G; Styk A; Kawecki M; Szczylik C; Czepko R; Banach M; Kaspera W; Szopa W; Bujko M; Czapski B; Zabek M; Iżycka-Świeszewska E; Kloc W; Nauman P; Cieslewicz J; Grajkowska W; Morosini N; Noushmehr H; Wojtas B; Kaminska B
Int J Cancer; 2023 Sep; 153(5):1003-1015. PubMed ID: 37338006
[TBL] [Abstract] [Full Text] [Related]
3. An
Özbek M; Toy HI; Oktay Y; Karakülah G; Suner A; Pavlopoulou A
PeerJ; 2023; 11():e15096. PubMed ID: 36945359
[TBL] [Abstract] [Full Text] [Related]
4. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability.
Luo Z; Xin D; Liao Y; Berry K; Ogurek S; Zhang F; Zhang L; Zhao C; Rao R; Dong X; Li H; Yu J; Lin Y; Huang G; Xu L; Xin M; Nishinakamura R; Yu J; Kool M; Pfister SM; Roussel MF; Zhou W; Weiss WA; Andreassen P; Lu QR
Nat Commun; 2023 Feb; 14(1):762. PubMed ID: 36765089
[TBL] [Abstract] [Full Text] [Related]
5. Glioma Subtypes Based on the Activity Changes of Immunologic and Hallmark Gene Sets in cancer.
Chen S
Front Endocrinol (Lausanne); 2022; 13():879233. PubMed ID: 35774141
[TBL] [Abstract] [Full Text] [Related]
6. Comparative analysis of transcriptomic profile, histology, and IDH mutation for classification of gliomas.
Tran PMH; Tran LKH; Nechtman J; Dos Santos B; Purohit S; Satter KB; Dun B; Kolhe R; Sharma S; Bollag R; She JX
Sci Rep; 2020 Nov; 10(1):20651. PubMed ID: 33244057
[TBL] [Abstract] [Full Text] [Related]
7. Multivariate analysis reveals differentially expressed genes among distinct subtypes of diffuse astrocytic gliomas: diagnostic implications.
González-García N; Nieto-Librero AB; Vital AL; Tao HJ; González-Tablas M; Otero Á; Galindo-Villardón P; Orfao A; Tabernero MD
Sci Rep; 2020 Jul; 10(1):11270. PubMed ID: 32647207
[TBL] [Abstract] [Full Text] [Related]
8. The Inhibition of miR-144-3p on Cell Proliferation and Metastasis by Targeting top2a in HCMV-Positive Glioblastoma Cells.
Song J; Ma Q; Hu M; Qian D; Wang B; He N
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544723
[TBL] [Abstract] [Full Text] [Related]
9. Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines.
Aaberg-Jessen C; Fogh L; Sørensen MD; Halle B; Brünner N; Kristensen BW
Pathol Oncol Res; 2019 Jan; 25(1):59-69. PubMed ID: 28963609
[TBL] [Abstract] [Full Text] [Related]
10. BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy.
Zheng HC; Li J; Shen DF; Yang XF; Zhao S; Wu YZ; Takano Y; Sun HZ; Su RJ; Luo JS; Gou WF
Oncotarget; 2015 Aug; 6(23):19685-705. PubMed ID: 26050197
[TBL] [Abstract] [Full Text] [Related]
11. Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a top2a inhibitor.
Arivazhagan A; Kumar DM; Sagar V; Patric IR; Sridevi S; Thota B; Srividya MR; Prasanna K; Thennarasu K; Mondal N; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
J Neurooncol; 2012 Apr; 107(2):289-97. PubMed ID: 22102081
[TBL] [Abstract] [Full Text] [Related]
